CER - Central Repository
Institute of Chemistry, Technology and Metallurgy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   Central Repository
  • IHTM
  • Radovi istraživača / Researchers' publications
  • View Item
  •   Central Repository
  • IHTM
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Edaravone May Prevent Ferroptosis in ALS

Thumbnail
2020
2020_edaravon_sspasic.pdf (979.9Kb)
Authors
Spasić, Snežana
Nikolić-Kokić, Aleksandra
Miletić, Srđan
Oreščanin-Dušić, Zorana
Spasić, Mihajlo
Blagojević, Duško
Stević, Zorica
Article (Accepted Version)
Metadata
Show full item record
Abstract
Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.
Keywords:
Edaravone / amyotrophic lateral sclerosis (ALS) / ferroptosis / therapy / neurons / neurodegeneration
Source:
Current Drug Targets, 2020, 21, 8, 776-780
Publisher:
  • Bentham Science
Projects:
  • Molecular mechanisms of redox signalling in homeostasis: adaptation and pathology (RS-173014)
Note:
  • This is the peer-reviewed version of the article: Spasic, Snezana; Nikolic-Kokic, Aleksandra; Miletic, Srdan; Orescanin-Dusic, Zorana; Spasic, Mihajlo B; Blagojevic, Dusko; Stevic, Zorica. Curr Drug Targets ; 21(8): 776-780, 2020, doi: https://doi.org/10.2174/1389450121666200220123305

DOI: 10.2174/1389450121666200220123305

ISSN: 1389-4501

WoS: 000542986600002

Scopus: 2-s2.0-85087096289
[ Google Scholar ]
2
3
URI
https://www.eurekaselect.com/179582/article
https://cer.ihtm.bg.ac.rs/handle/123456789/3966
Collections
  • Radovi istraživača / Researchers' publications
Institution
IHTM

DSpace software copyright © 2002-2015  DuraSpace
About CeR – Central Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About CeR – Central Repository | Send Feedback

OpenAIRERCUB